Viridian Therapeutics (VRDN) closed at $19.03 on October 16, 2026, down 2.7% from the previous close, on volume of 2,189,554 shares (30-day average 1,850,262).
Data as of October 16, 2026.
16-Oct-2026
TipRanks (Wed, 14-Oct 6:50 AM ET)
Business Wire (Thu, 6-Aug 7:01 AM ET)
Market Chameleon (Thu, 7-May 4:17 AM ET)
Viridian Therapeutics Prepares for TED Launch with Positive Clinical Data and $762M Cash Reserve
Market Chameleon (Tue, 5-May 4:02 AM ET)
Viridian’s Elegrobart Achieves Major Milestones with Strong Phase 3 Results in Thyroid Eye Disease
Market Chameleon (Mon, 30-Mar 3:29 AM ET)
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.
As of October 16, 2026, VRDN stock price declined to $19.03 with 2,189,554 million shares trading.
VRDN has a beta of -0.58, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.01 to the broad based SPY ETF.
VRDN has a market cap of $2.16 billion. This is considered a Mid Cap stock.
Last quarter Viridian Therapeutics reported $233,000 in Revenue and -$1.05 earnings per share. This beat revenue expectation by $211,000 and missed earnings estimates by -$.03.
In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.
The top ETF exchange traded funds that VRDN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
VRDN has underperformed the market in the last year with a price return of -17.3% while the SPY ETF gained +16.7%. However, in the short term, VRDN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.5% vs +1.9% return in SPY. But in the last 2 weeks, VRDN shares have been beat by the market, returning -1.9% compared to an SPY return of -0.8%.
VRDN support price is $18.97 and resistance is $20.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.
